The DNA damage repair landscape in Black women with breast cancer

Background: Estrogen receptor positive (ER+) breast cancer is one of the most commonly diagnosed malignancies in women irrespective of their race or ethnicity. While Black women with ER+ breast cancer are 42% more likely to die of their disease than White women, molecular mechanisms underlying this disparate outcome are understudied. Recent studies identify DNA damage repair (DDR) genes as a new class of endocrine therapy resistance driver that contributes to poor survival among ER+ breast cancer patients. Here, we systematically analyze DDR regulation in the tumors and normal breast of Black women and its impact on survival outcome.
Method: Mutation and up/downregulation of 104 DDR genes in breast tumor and normal samples from Black patients relative to White counterparts was assessed. For DDR genes that were differently regulated in the tumor samples from Black women in multiple datasets associations with survival outcome were tested.
Results: Overall, Black patient tumors upregulate or downregulate RNA levels of a wide array of single strand break repair (SSBR) genes relative to their white counterparts and uniformly upregulate double strand break repair (DSBR) genes. This DSBR upregulation was also detectable in samples of normal breast tissue from Black women. Eight candidate DDR genes were reproducibly differently regulated in tumors from Black women and associated with poor survival. A unique DDR signature comprised of simultaneous upregulation of homologous recombination gene expression and downregulation of SSBR genes was enriched in Black patients. This signature associated with cell cycle dysregulation (p < 0.001), a hallmark of endocrine therapy resistance, and concordantly, with significantly worse survival outcomes in all datasets analyzed (hazard ratio of 9.5, p < 0.001).
Conclusion: These results constitute the first systematic analysis of DDR regulation in Black women and provide strong rationale for refining biomarker profiles to ensure precision medicine for underserved populations.

DNA damage-induced translocation of mitochondrial factor HIGD1A into the nucleus regulates homologous recombination and radio/chemo-sensitivity

HIGD1A is an important mitochondrial protein recently shown to have a novel nuclear localization under severe stress. However, whether this protein is also associated with the DNA damage response has rarely been studied. Here, we reported that DSBs-induced the translocation of mitochondrial HIGD1A to the nucleus is dependent on nuclear pore complex (NPCs), which finally promotes HR and radio/chemo-resistance. Importantly, NUP93 and HIGD1A physically interact and the interaction domain with NUP93 is located at residues 46-60 of HIGD1A. Chromatin-enriched HIGD1A can then directly interact with RPA.
During the early stages of HR, HIGD1A promotes the loading of RPA to DSBs and activates the DNA damage-dependent chromatin association of RAD9-RAD1-HUS1 complex (9-1-1), which stimulates the ATR-Chk1-dependent G2/M DNA damage checkpoint. After facilitating RPA-ssDNA binding, HIGD1A in turn inhibits abnormal persistence of RPA1 foci by promoting ubiquitination of RPA1 and inducing its eventual proteasomal degradation. In addition, we have identified clinical drug Preveon associated with the HIGD1A-NUP93 interaction domain using a virtual screening approach. This compound directly interacted with HIGD1A, which was verified by NMR, and then inhibited HIGD1A translocation. Collectively, we demonstrate a novel role for HIGD1A in DSBs and provide rationale for using HIGD1A inhibitors as cancer therapeutics.

Retrotransposons as a Source of DNA Damage in Neurodegeneration

The etiology of aging-associated neurodegenerative diseases (NDs), such as Parkinson’s disease (PD) and Alzheimer’s disease (AD), still remains elusive and no curative treatment is available. Age is the major risk factor for PD and AD, but the molecular link between aging and neurodegeneration is not fully understood. Aging is defined by several hallmarks, some of which partially overlap with pathways implicated in NDs. Recent evidence suggests that aging-associated epigenetic alterations can lead to the derepression of the LINE-1 (Long Interspersed Element-1) family of transposable elements (TEs) and that this derepression might have important implications in the pathogenesis of NDs.
Almost half of the human DNA is composed of repetitive sequences derived from TEs and TE mobility participated in shaping the mammalian genomes during evolution. Although most TEs are mutated and no longer mobile, more than 100 LINE-1 elements have retained their full coding potential in humans and are thus retrotransposition competent. Uncontrolled activation of TEs has now been reported in various models of neurodegeneration and in diseased human brain tissues. We will discuss in this review the potential contribution of LINE-1 elements in inducing DNA damage and genomic instability, which are emerging pathological features in NDs. TEs might represent an important molecular link between aging and neurodegeneration, and a potential target for urgently needed novel therapeutic disease-modifying interventions.

Extended Prophylactic Effect of N-tert-Butyl-α-phenylnitron against Oxidative/Nitrosative Damage Caused by the DNA-Hypomethylating Drug 5-Azacytidine in the Rat Placenta

Antioxidant N-tert-Butyl-α-phenylnitron (PBN) partly protected embryos from the negative effects of a DNA demethylating drug 5-azacytidine during pregnancy. Our aim was to investigate PBN’s impact on the placenta. Fischer rat dams were treated on gestation days (GD) 12 and 13 by PBN (40 mg/kg), followed by 5azaC (5 mg/kg) after one hour. Global methylation was assessed by pyrosequencing. Numerical density was calculated from immunohistochemical expression in single cells for proliferating (PCNA), oxidative (oxoguanosine) and nitrosative (nitrotyrosine) activity.
Results were compared with the PBN-treated and control rats. PBN-pretreatment significantly increased placental weight at GD15 and GD20, diminished by 5azaC, and diminished apoptosis in GD 20 placentas caused by 5azaC. Oxoguanosine expression in placentas of 5azaC-treated dams was especially high in the placental labyrinth on GD 15, while PBN-pretreatment lowered its expression on GD 15 and GD 20 in both the labyrinth and basal layer. 5azaC enhanced nitrotyrosine level in the labyrinth of both gestational stages, while PBN-pretreatment lowered it. We conclude that PBN exerted its prophylactic activity against DNA hypomethylating agent 5azaC in the placenta through free radical scavenging, especially in the labyrinthine part of the placenta until the last day of pregnancy.

DNA Damage Quantification Kit

55R-1345 Fitzgerald 25 assays 1012.8 EUR

DNA / RNA Damage Antibody

abx444253-100ug Abbexa 100 ug 661.2 EUR

DNA / RNA Damage Antibody

abx444534-100ug Abbexa 100 ug 661.2 EUR

DNA / RNA Damage Antibody

20-abx444884 Abbexa
  • 594.00 EUR
  • 393.60 EUR
  • 100 ug
  • 25 ug

DNA / RNA Damage Antibody

abx440040-100ug Abbexa 100 ug 661.2 EUR

DNA / RNA Damage Antibody

abx440321-100ug Abbexa 100 ug 661.2 EUR

DNA / RNA Damage Antibody

abx440602-100ug Abbexa 100 ug 661.2 EUR

DNA / RNA Damage Antibody

abx440883-100ug Abbexa 100 ug 661.2 EUR

DNA / RNA Damage Antibody

abx441164-100ug Abbexa 100 ug 661.2 EUR

DNA / RNA Damage Antibody

abx441445-100ug Abbexa 100 ug 661.2 EUR

DNA / RNA Damage Antibody

abx441726-100ug Abbexa 100 ug 661.2 EUR

DNA / RNA Damage Antibody

abx442007-100ug Abbexa 100 ug 661.2 EUR

DNA / RNA Damage Antibody

abx442850-100ug Abbexa 100 ug 661.2 EUR

DNA / RNA Damage Antibody

abx443130-100ug Abbexa 100 ug 661.2 EUR

DNA / RNA Damage Antibody

abx443410-100ug Abbexa 100 ug 644.4 EUR

DNA / RNA Damage Antibody

abx443691-100ug Abbexa 100 ug 678 EUR

DNA / RNA Damage Antibody

abx443972-100ug Abbexa 100 ug 661.2 EUR

DNA / RNA Damage Antibody

abx442288-100ug Abbexa 100 ug 661.2 EUR

DNA / RNA Damage Antibody

abx442569-100ug Abbexa 100 ug 661.2 EUR

VAHTS DNA Damage Repair Kit

N208-01 Vazyme 24 rxn 315.6 EUR

VAHTS DNA Damage Repair Kit

N208-02 Vazyme 96 rxn 770.4 EUR

DiscoveryProbe? DNA Damage/DNA Repair Library

L1033-.1 ApexBio 100 uL/well(10 mM solution) 4666.8 EUR

DiscoveryProbe? DNA Damage/DNA Repair Library

L1033-.25 ApexBio 250 uL/well(10 mM solution) 8286 EUR

DiscoveryProbe? DNA Damage/DNA Repair Library

L1033-5 ApexBio 5 mg/well 10806 EUR

DNA Damage (8-OHdG) ELISA Kit

abx259909-96well Abbexa 96 well 904.8 EUR

DNA Damage ELISA Kit (1 Plate)

K059-H1 Arbor Assays 1x96 well plate 595 EUR

Interaction among noncoding RNAs, DNA damage reactions, and genomic instability in the hypoxic tumor: is it therapeutically exploitable practice?

  • Hypoxia is a classical function of the tumor’s microenvironment with a substantial effect on the development and therapeutic response of cancer. The hypoxic tumor is a chaotic battle and adaptive landscape. When put in hypoxic environments, cells undergo several biological reactions, including activation of signaling pathways that control proliferation, angiogenesis, and death. These pathways have been adapted by cancer cells to allow tumors to survive and even develop in hypoxic conditions, and poor prognosis is associated with tumor hypoxia.
  • The most relevant transcriptional regulator in response to hypoxia, Hypoxia-inducible factor-1 alpha (HIF-1α), has been shown to modulate hypoxic gene expression and signaling transduction networks significantly. The significance of non-coding RNAs in hypoxic tumor regions has been revealed in an increasing number of studies over the past few decades. In regulating hypoxic gene expression, these hypoxia-responsive ncRNAs play pivotal roles. Hypoxia, a general characteristic of the tumor’s microenvironment, significantly affects the expression of genes and is closely associated with the development of cancer.
  • Indeed the number of known hypoxia-associated lncRNAs has increased dramatically, demonstrating the growing role of lncRNAs in cascades and responses to hypoxia signaling. Decades of research have helped us create an image of the shift in hypoxic cancer cells’ DNA repair capabilities. Emerging evidence suggests that hypoxia can trigger genetic instability in cancer cells because of microenvironmental tumor stress.
  • Researchers have found that critical genes’ expression is coordinately repressed by hypoxia within the DNA damage and repair pathways. In this study, we include an update of current knowledge on the presentation, participation, and potential clinical effect of ncRNAs in tumor hypoxia, DNA damage reactions, and genomic instability, with a specific emphasis on their unusual cascade of molecular regulation and malignant progression induced by hypoxia.

Leave a Comment

Your email address will not be published.

Scroll to Top